Literature DB >> 29463554

Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma.

Joanna Przybyl1, Jacob J Chabon2,3, Lien Spans4, Kristen N Ganjoo5, Sujay Vennam6, Aaron M Newman2,3, Erna Forgó6, Sushama Varma6, Shirley Zhu6, Maria Debiec-Rychter4, Ash A Alizadeh2,3, Maximilian Diehn2,3, Matt van de Rijn6.   

Abstract

Purpose: The clinical utility of circulating tumor DNA (ctDNA) monitoring has been shown in tumors that harbor highly recurrent mutations. Leiomyosarcoma represents a type of tumor with a wide spectrum of heterogeneous genomic abnormalities; thus, targeting hotspot mutations or a narrow genomic region for ctDNA detection may not be practical. Here, we demonstrate a combinatorial approach that integrates different sequencing protocols for the orthogonal detection of single-nucleotide variants (SNV), small indels, and copy-number alterations (CNA) in ctDNA.Experimental Design: We employed Cancer Personalized Profiling by deep Sequencing (CAPP-Seq) for the analysis of SNVs and indels, together with a genome-wide interrogation of CNAs by Genome Representation Profiling (GRP). We profiled 28 longitudinal plasma samples and 25 tumor specimens from 7 patients with leiomyosarcoma.
Results: We detected ctDNA in 6 of 7 of these patients with >98% specificity for mutant allele fractions down to a level of 0.01%. We show that results from CAPP-Seq and GRP are highly concordant, and the combination of these methods allows for more comprehensive monitoring of ctDNA by profiling a wide spectrum of tumor-specific markers. By analyzing multiple tumor specimens in individual patients obtained from different sites and at different times during treatment, we observed clonal evolution of these tumors that was reflected by ctDNA profiles.Conclusions: Our strategy allows for the comprehensive monitoring of a broad spectrum of tumor-specific markers in plasma. Our approach may be clinically useful not only in leiomyosarcoma but also in other tumor types that lack recurrent genomic alterations. Clin Cancer Res; 24(11); 2688-99. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Year:  2018        PMID: 29463554      PMCID: PMC5984700          DOI: 10.1158/1078-0432.CCR-17-3704

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  44 in total

1.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing.

Authors:  Daniel C Koboldt; Qunyuan Zhang; David E Larson; Dong Shen; Michael D McLellan; Ling Lin; Christopher A Miller; Elaine R Mardis; Li Ding; Richard K Wilson
Journal:  Genome Res       Date:  2012-02-02       Impact factor: 9.043

2.  A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data.

Authors:  Heng Li
Journal:  Bioinformatics       Date:  2011-09-08       Impact factor: 6.937

3.  Noninvasive prenatal testing using a novel analysis pipeline to screen for all autosomal fetal aneuploidies improves pregnancy management.

Authors:  Baran Bayindir; Luc Dehaspe; Nathalie Brison; Paul Brady; Simon Ardui; Molka Kammoun; Lars Van der Veken; Klaske Lichtenbelt; Kris Van den Bogaert; Jeroen Van Houdt; Hilde Peeters; Hilde Van Esch; Thomy de Ravel; Eric Legius; Koen Devriendt; Joris R Vermeesch
Journal:  Eur J Hum Genet       Date:  2015-01-14       Impact factor: 4.246

4.  Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.

Authors:  Jianjun Zhang; Junya Fujimoto; Jianhua Zhang; David C Wedge; Xingzhi Song; Jiexin Zhang; Sahil Seth; Chi-Wan Chow; Yu Cao; Curtis Gumbs; Kathryn A Gold; Neda Kalhor; Latasha Little; Harshad Mahadeshwar; Cesar Moran; Alexei Protopopov; Huandong Sun; Jiabin Tang; Xifeng Wu; Yuanqing Ye; William N William; J Jack Lee; John V Heymach; Waun Ki Hong; Stephen Swisher; Ignacio I Wistuba; P Andrew Futreal
Journal:  Science       Date:  2014-10-10       Impact factor: 47.728

5.  The metalloprotease ADAMTS8 displays antitumor properties through antagonizing EGFR-MEK-ERK signaling and is silenced in carcinomas by CpG methylation.

Authors:  Gigi C G Choi; Jisheng Li; Yajun Wang; Lili Li; Lan Zhong; Brigette Ma; Xianwei Su; Jianming Ying; Tingxiu Xiang; Sun Young Rha; Jun Yu; Joseph J Y Sung; Sai Wah Tsao; Anthony T C Chan; Qian Tao
Journal:  Mol Cancer Res       Date:  2013-11-01       Impact factor: 5.852

6.  Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Authors:  Christopher Abbosh; Nicolai J Birkbak; Gareth A Wilson; Mariam Jamal-Hanjani; Tudor Constantin; Raheleh Salari; John Le Quesne; David A Moore; Selvaraju Veeriah; Rachel Rosenthal; Teresa Marafioti; Eser Kirkizlar; Thomas B K Watkins; Nicholas McGranahan; Sophia Ward; Luke Martinson; Joan Riley; Francesco Fraioli; Maise Al Bakir; Eva Grönroos; Francisco Zambrana; Raymondo Endozo; Wenya Linda Bi; Fiona M Fennessy; Nicole Sponer; Diana Johnson; Joanne Laycock; Seema Shafi; Justyna Czyzewska-Khan; Andrew Rowan; Tim Chambers; Nik Matthews; Samra Turajlic; Crispin Hiley; Siow Ming Lee; Martin D Forster; Tanya Ahmad; Mary Falzon; Elaine Borg; David Lawrence; Martin Hayward; Shyam Kolvekar; Nikolaos Panagiotopoulos; Sam M Janes; Ricky Thakrar; Asia Ahmed; Fiona Blackhall; Yvonne Summers; Dina Hafez; Ashwini Naik; Apratim Ganguly; Stephanie Kareht; Rajesh Shah; Leena Joseph; Anne Marie Quinn; Phil A Crosbie; Babu Naidu; Gary Middleton; Gerald Langman; Simon Trotter; Marianne Nicolson; Hardy Remmen; Keith Kerr; Mahendran Chetty; Lesley Gomersall; Dean A Fennell; Apostolos Nakas; Sridhar Rathinam; Girija Anand; Sajid Khan; Peter Russell; Veni Ezhil; Babikir Ismail; Melanie Irvin-Sellers; Vineet Prakash; Jason F Lester; Malgorzata Kornaszewska; Richard Attanoos; Haydn Adams; Helen Davies; Dahmane Oukrif; Ayse U Akarca; John A Hartley; Helen L Lowe; Sara Lock; Natasha Iles; Harriet Bell; Yenting Ngai; Greg Elgar; Zoltan Szallasi; Roland F Schwarz; Javier Herrero; Aengus Stewart; Sergio A Quezada; Karl S Peggs; Peter Van Loo; Caroline Dive; C Jimmy Lin; Matthew Rabinowitz; Hugo J W L Aerts; Allan Hackshaw; Jacqui A Shaw; Bernhard G Zimmermann; Charles Swanton
Journal:  Nature       Date:  2017-04-26       Impact factor: 49.962

7.  Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing.

Authors:  Ellen Heitzer; Peter Ulz; Jelena Belic; Stefan Gutschi; Franz Quehenberger; Katja Fischereder; Theresa Benezeder; Martina Auer; Carina Pischler; Sebastian Mannweiler; Martin Pichler; Florian Eisner; Martin Haeusler; Sabine Riethdorf; Klaus Pantel; Hellmut Samonigg; Gerald Hoefler; Herbert Augustin; Jochen B Geigl; Michael R Speicher
Journal:  Genome Med       Date:  2013-04-05       Impact factor: 15.266

8.  NCBI's Database of Genotypes and Phenotypes: dbGaP.

Authors:  Kimberly A Tryka; Luning Hao; Anne Sturcke; Yumi Jin; Zhen Y Wang; Lora Ziyabari; Moira Lee; Natalia Popova; Nataliya Sharopova; Masato Kimura; Michael Feolo
Journal:  Nucleic Acids Res       Date:  2013-12-01       Impact factor: 16.971

9.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962

10.  Integrated digital error suppression for improved detection of circulating tumor DNA.

Authors:  Aaron M Newman; Alexander F Lovejoy; Daniel M Klass; David M Kurtz; Jacob J Chabon; Florian Scherer; Henning Stehr; Chih Long Liu; Scott V Bratman; Carmen Say; Li Zhou; Justin N Carter; Robert B West; George W Sledge; Joseph B Shrager; Billy W Loo; Joel W Neal; Heather A Wakelee; Maximilian Diehn; Ash A Alizadeh
Journal:  Nat Biotechnol       Date:  2016-03-28       Impact factor: 54.908

View more
  16 in total

Review 1.  Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).

Authors:  Re-I Chin; Kevin Chen; Abul Usmani; Chanelle Chua; Peter K Harris; Michael S Binkley; Tej D Azad; Jonathan C Dudley; Aadel A Chaudhuri
Journal:  Mol Diagn Ther       Date:  2019-06       Impact factor: 4.074

2.  CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M-positive lung cancer after osimertinib.

Authors:  Ryoji Kato; Hidetoshi Hayashi; Kazuko Sakai; Shinichiro Suzuki; Koji Haratani; Takayuki Takahama; Junko Tanizaki; Yoshikane Nonagase; Kaoru Tanaka; Takeshi Yoshida; Masayuki Takeda; Kimio Yonesaka; Hiroyasu Kaneda; Kazuto Nishio; Kazuhiko Nakagawa
Journal:  Int J Clin Oncol       Date:  2021-06-11       Impact factor: 3.402

3.  KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition.

Authors:  Michael S Binkley; Young-Jun Jeon; Monica Nesselbush; Everett J Moding; Barzin Y Nabet; Diego Almanza; Christian Kunder; Henning Stehr; Christopher H Yoo; Siyeon Rhee; Michael Xiang; Jacob J Chabon; Emily Hamilton; David M Kurtz; Linda Gojenola; Susie Grant Owen; Ryan B Ko; June Ho Shin; Peter G Maxim; Natalie S Lui; Leah M Backhus; Mark F Berry; Joseph B Shrager; Kavitha J Ramchandran; Sukhmani K Padda; Millie Das; Joel W Neal; Heather A Wakelee; Ash A Alizadeh; Billy W Loo; Maximilian Diehn
Journal:  Cancer Discov       Date:  2020-10-18       Impact factor: 38.272

Review 4.  Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors.

Authors:  Kevin Chen; Misty D Shields; Pradeep S Chauhan; Ricardo J Ramirez; Peter K Harris; Melissa A Reimers; Jose P Zevallos; Andrew A Davis; Bruna Pellini; Aadel A Chaudhuri
Journal:  Mol Diagn Ther       Date:  2021-11-01       Impact factor: 4.476

5.  The Circulating Nucleic Acid Characteristics of Non-Metastatic Soft Tissue Sarcoma Patients.

Authors:  Nicholas Eastley; Aurore Sommer; Barbara Ottolini; Rita Neumann; Jin-Li Luo; Robert K Hastings; Thomas McCulloch; Claire P Esler; Jacqueline A Shaw; Robert U Ashford; Nicola J Royle
Journal:  Int J Mol Sci       Date:  2020-06-24       Impact factor: 5.923

6.  Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing.

Authors:  Naoyuki Iwahashi; Kazuko Sakai; Tomoko Noguchi; Tamaki Yahata; Hitomi Matsukawa; Saori Toujima; Kazuto Nishio; Kazuhiko Ino
Journal:  Sci Rep       Date:  2019-07-18       Impact factor: 4.379

7.  High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.

Authors:  Pedram Razavi; Bob T Li; David N Brown; Byoungsok Jung; Earl Hubbell; Ronglai Shen; Wassim Abida; Krishna Juluru; Ino De Bruijn; Chenlu Hou; Oliver Venn; Raymond Lim; Aseem Anand; Tara Maddala; Sante Gnerre; Ravi Vijaya Satya; Qinwen Liu; Ling Shen; Nicholas Eattock; Jeanne Yue; Alexander W Blocker; Mark Lee; Amy Sehnert; Hui Xu; Megan P Hall; Angie Santiago-Zayas; William F Novotny; James M Isbell; Valerie W Rusch; George Plitas; Alexandra S Heerdt; Marc Ladanyi; David M Hyman; David R Jones; Monica Morrow; Gregory J Riely; Howard I Scher; Charles M Rudin; Mark E Robson; Luis A Diaz; David B Solit; Alexander M Aravanis; Jorge S Reis-Filho
Journal:  Nat Med       Date:  2019-11-25       Impact factor: 53.440

8.  Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors.

Authors:  César Serrano; Ana Vivancos; Antonio López-Pousa; Judit Matito; Francesco M Mancuso; Claudia Valverde; Sergi Quiroga; Stefania Landolfi; Sandra Castro; Cristina Dopazo; Ana Sebio; Anna C Virgili; María M Menso; Javier Martín-Broto; Miriam Sansó; Alfonso García-Valverde; Jordi Rosell; Jonathan A Fletcher; Suzanne George; Joan Carles; Joaquín Arribas
Journal:  BMC Cancer       Date:  2020-02-05       Impact factor: 4.430

9.  Detection of Circulating Tumor DNA in Patients With Leiomyosarcoma With Progressive Disease.

Authors:  Matthew L Hemming; Kelly S Klega; Justin Rhoades; Gavin Ha; Kate E Acker; Jessica L Andersen; Edwin Thai; Anwesha Nag; Aaron R Thorner; Chandrajit P Raut; Suzanne George; Brian D Crompton
Journal:  JCO Precis Oncol       Date:  2019-01-24

10.  A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis.

Authors:  Nam Q Bui; Joanna Przybyl; Sally E Trabucco; Garrett Frampton; Trevor Hastie; Matt van de Rijn; Kristen N Ganjoo
Journal:  Clin Sarcoma Res       Date:  2019-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.